Skip to main content
Premium Trial:

Request an Annual Quote

Gentel to Collaborate with SCOPE Consortium

NEW YORK (GenomeWeb News) – Gentel Biosciences will collaborate with an international consortium focused on developing biomarkers for pregnancy complications, the company said.

The Screening for Pregnancy Endpoints (SCOPE) Study is establishing a pregnancy biobank that will be used to research tests that can predict major diseases of late-stage pregnancy, which affect 19 percent of worldwide pregnancies, the company said.

"Our goal is to develop a high performance screening test for preeclampsia" using Gentel's Apix Array platform, SCOPE Project Leader and University of Adelaide Professor Robyn North said in a statement.

Madison, Wis.-based GenTel will develop and validate a quantitative multiplex immunoassay using its microarray technologies to measure a large panel of analytes.

Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.